

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report: January 3, 2005

LIFELINE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Colorado ----- (State or other jurisdiction of incorporation)	000-30489 ----- (Commission File Number)	84-1097796 ----- (IRS Employer Identification No.)
---	---	---

6400 South Fiddler's Green Circle, Englewood, CO 80111

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (720) 488-1711

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

Item 4.01 Changes in Registrant's Certifying Accountant

On December 30, 2004, the Board of Directors of Lifeline Therapeutics, Inc.
("Lifeline" or the "Company") informed Michael Johnson & Co., LLC that it has
dismissed Michael Johnson & Co., LLC as the Company's independent registered
public accounting firm effective immediately.

On December 30, 2004, the Board of Directors informed Gordon, Banks &
Hughes, LLP, certified public accountants, that such firm was appointed as the
Company's independent registered public accounting firm effective immediately.
The Company has authorized Michael Johnson & Co., LLC to respond fully to
inquiries by our new auditors in connection with the retention of the new
auditors.

Michael Johnson & Co's reports on the Company's financial statements for
the fiscal years ended December 31, 2002 and December 31, 2003 did not contain
an adverse opinion or disclaimer of opinion and were not qualified or modified
as to uncertainty, audit scope, or accounting principle, except for the matter
discussed in the next sentence. There was an explanatory paragraph in Michael
Johnson & Co.'s report on the Company's financial statements included in the
Form 10-KSB for the years ended December 31, 2002 and December 31, 2003, both of
which indicated that the accompanying financial statements had been prepared
assuming that the Company will continue as a going concern, and Michael Johnson
& Co. indicated that for both fiscal years conditions exist that raise
substantial doubt about the Company's ability to continue as a going concern.

In connection with the audits of the Company's financial statements for

each of the last two fiscal years ended December 31, 2002 and December 31, 2003, and as of December 30, 2004, there were no disagreements between the Company and Michael Johnson & Co. on any matter of accounting principles or practices, consolidated financial statement disclosures, or auditing scope and procedures, which, if not resolved to the satisfaction of Michael Johnson & Co., would have caused them to make reference thereto in connection with their report on the financial statements.

During the Company's past two fiscal years and through December 30, 2004, we did not consult Gordon, Banks & Hughes, LLP regarding the application of accounting principles to a specific transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, or any other matter or reportable event that would be required to be reported in this Form 8-K.

We have provided to Michael Johnson & Co. a copy of these disclosures and have requested that Michael Johnson & Co. furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether Michael Johnson & Co. agrees with the statements by the Company in this report. Michael Johnson & Co.'s letter is attached as Exhibit 16.1.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

The following exhibits are included with this filing.

- 16.1 Letter of Michael Johnson & Co., LLC dated January 3, 2005 regarding the change in certifying accountants.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 3, 2005

LIFELINE THERAPEUTICS, INC.

By: /s/ William J. Driscoll

William J. Driscoll, CEO/President

January 3, 2005

U.S. Securities and Exchange Commission
Office of the Chief Accountant
450 Fifth Street, NW
Washington, DC 20549

Re: Lifeline Therapeutics, Inc.

Dear Sir or Madam:

We have read Item 4.01 of Form 8-K of Lifeline Therapeutics, Inc. dated January 3, 2005, and agree with the statements concerning our Firm contained therein.

Very truly yours,

/s/ MICHAEL JOHNSON & CO., LLC